BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
Xiaoyan Yang, Peng Feng, Xiangjian Zhang, Dongfang Li, Ruifang Wang, Chenhui Ji, Guanglai Li, Christian Hölscher. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of strokeNeuropharmacology 2019; 158: 107748 doi: 10.1016/j.neuropharm.2019.107748
Neil Skolnik, Renell S. Dupree, Eric L. Johnson. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agentsCurrent Medical Research and Opinion 2017; 33(12): 2187 doi: 10.1080/03007995.2017.1359518
Gerhard H. Scholz, Holger Fleischmann. Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingTherapeutic Advances in Endocrinology and Metabolism 2014; 5(5): 95 doi: 10.1177/2042018814556099
Tina Vilsbøll, Jiten Vora, Henrik Jarlov, Kajsa Kvist, Lawrence Blonde. Type 2 Diabetes Patients Reach Target Glycemic Control Faster Using IDegLira than Either Insulin Degludec or Liraglutide Given AloneClinical Drug Investigation 2016; 36(4): 293 doi: 10.1007/s40261-016-0376-0
Paula L. McClean, Christian Hölscher. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's diseaseNeuropharmacology 2014; 86: 241 doi: 10.1016/j.neuropharm.2014.07.015
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes, Flávio Reis. The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?Journal of Diabetes Research 2015; 2015: 1 doi: 10.1155/2015/806979
Sarah L. Greig, Lesley J. Scott. Insulin Degludec/Liraglutide: A Review in Type 2 DiabetesDrugs 2015; 75(13): 1523 doi: 10.1007/s40265-015-0448-0
Mie Tonoike, Daisuke Chujo, Mitsuhiko Noda. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetesEndocrinology, Diabetes & Metabolism 2019; 2(1): e00043 doi: 10.1002/edm2.43
Jennifer D. Goldman-Levine. Combination Therapy When Metformin Is Not an Option for Type 2 DiabetesAnnals of Pharmacotherapy 2015; 49(6): 688 doi: 10.1177/1060028015572653
Takahisa Hirose, Manabu Suzuki, Isao Tsumiyama. Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized StudyDiabetes Therapy 2015; 6(4): 559 doi: 10.1007/s13300-015-0147-6
Shigeo Fuji, Sung-Won Kim, Shigemi Kamiya, Takahiko Nakane, Kenji Matsumoto, Yasushi Onishi, Kimikazu Yakushijin, Etsuko Yamazaki, Masayuki Hino, Saiko Kurosawa, Ken-ichi Yoshimura, Takahiro Fukuda. A multi-center prospective study randomizing the use of fat emulsion in intensive glucose control after allogeneic hematopoietic stem cell transplantation using a myeloablative conditioning regimenClinical Nutrition 2018; 37(5): 1534 doi: 10.1016/j.clnu.2017.08.022
Bo Ahrén. Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?Diabetologia 2015; 58(8): 1740 doi: 10.1007/s00125-015-3557-0
Richard Simpson, Allen King. Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?Expert Review of Clinical Pharmacology 2015; 8(2): 179 doi: 10.1586/17512433.2015.1017562
Marcus Lind, Irl B. Hirsch, Jaakko Tuomilehto, Sofia Dahlqvist, Ole Torffvit, Nils-Gunnar Pehrsson. Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)Primary Care Diabetes 2015; 9(1): 15 doi: 10.1016/j.pcd.2014.07.010
Andrea Tura, Johan Farngren, Anja Schweizer, James E. Foley, Giovanni Pacini, Bo Ahrén. Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and VildagliptinInternational Journal of Endocrinology 2015; 2015: 1 doi: 10.1155/2015/484231
Lisa J. Underland, Jeniece Trast Ilkowitz, Ranjitha Katikaneni, Amy Dowd, Rubina A. Heptulla. Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 DiabetesJournal of Diabetes Science and Technology 2017; 11(3): 602 doi: 10.1177/1932296817699847
Jennifer Goldman, Jennifer M. Trujillo. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 DiabetesAnnals of Pharmacotherapy 2017; 51(11): 990 doi: 10.1177/1060028017717281
Aline Haas de Mello, Morgana Prá, Larissa Colonetti Cardoso, Rosiane de Bona Schraiber, Gislaine Tezza Rezin. Incretin-based therapies for obesity treatmentMetabolism 2015; 64(9): 967 doi: 10.1016/j.metabol.2015.05.012
Yasuo Terauchi, Yusuke Naito, Yukio Ikeda. Evaluation of unmet medical need among Japanese patients with type 2 diabetes mellitus and efficacy of Lixisenatide treatment among Asian type 2 diabetes mellitus patientsDiabetes & Metabolic Syndrome: Clinical Research & Reviews 2016; 10(1): 23 doi: 10.1016/j.dsx.2015.08.008
Cristina Mega, Edite Teixeira-de-Lemos, Rosa Fernandes, Flávio Reis. Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 DiabetesJournal of Diabetes Research 2017; 2017: 1 doi: 10.1155/2017/5164292
S Fuji, A Rovó, K Ohashi, M Griffith, H Einsele, M Kapp, M Mohty, N S Majhail, B G Engelhardt, A Tichelli, B N Savani. How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCTBone Marrow Transplantation 2016; 51(8): 1041 doi: 10.1038/bmt.2016.81
André J Scheen. A review of gliptins for 2014Expert Opinion on Pharmacotherapy 2015; 16(1): 43 doi: 10.1517/14656566.2015.978289
Lyudmila Alexandrovna Ruyatkina, Maxim Sorokin. Combined insulin detemir and liraglutide therapy in type 2 diabetic patients: a base for an allianceDiabetes mellitus 2017; 20(2): 142 doi: 10.14341/7875
Bo Ahrén. Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug developmentJournal of Diabetes Investigation 2019; 10(2): 196 doi: 10.1111/jdi.12911
B. Ahrén. Physiological aspects of the combination of insulin and GLP-1 in the regulation of blood glucose controlDiabetes & Metabolism 2015; 41(6): 6S3 doi: 10.1016/S1262-3636(16)30002-7
Yeong Gi Kim, Se Hee Min, Seokyung Hahn, Tae Jung Oh, Kyong Soo Park, Young Min Cho. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysisDiabetes Research and Clinical Practice 2016; 116: 86 doi: 10.1016/j.diabres.2016.03.011
Johan Farngren, Bo Ahrén. Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodesMetabolism 2019; 99: 25 doi: 10.1016/j.metabol.2019.06.016
Andrew J. Krentz, Christian Weyer, Marcus Hompesch. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease2019; : 75 doi: 10.1007/978-3-030-11748-1_3
Arun K. Sharma, Punniyakoti V. Thanikachalam, Satyendra K. Rajput. Albiglutide: Is a better hope against diabetes mellitus?Biomedicine & Pharmacotherapy 2016; 77: 120 doi: 10.1016/j.biopha.2015.12.015
R. G. Lentle, I. R. Sequeira, A. K. Hardacre, G. Reynolds. A method for assessing real time rates of dissolution and absorption of carbohydrate and other food matrices in human subjectsFood & Function 2016; 7(6): 2820 doi: 10.1039/C6FO00406G
Uchenna Anyanwagu, Jil Mamza, Richard Donnelly, Iskandar Idris. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort studyAmerican Heart Journal 2018; 196: 18 doi: 10.1016/j.ahj.2017.10.003
John C. Clapham. Type 2 DiabetesMethods in Molecular Biology 2020; 2076: 1 doi: 10.1007/978-1-4939-9882-1_1
Manel Mata-Cases, Dídac Mauricio, Josep Franch-Nadal. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targetsJournal of Diabetes 2017; 9(1): 34 doi: 10.1111/1753-0407.12373
Ohad Cohen, Sebastiano Filetti, Javier Castañeda, Marianna Maranghi, Mariela Glandt. When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin PumpDiabetes Care 2016; 39(Supplement 2): S180 doi: 10.2337/dcS15-3029